title: Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism.
abstract: The importance of iron in the growth and progression of tumors has been widely documented. In this report, we show that tumor-initiating cells (TICs), represented by spheres derived from the MCF7 cell line, exhibit higher intracellular labile iron pool, mitochondrial iron accumulation and are more susceptible to iron chelation. TICs also show activation of the IRP/IRE system, leading to higher iron uptake and decrease in iron storage, suggesting that level of properly assembled cytosolic iron-sulfur clusters (FeS) is reduced. This finding is confirmed by lower enzymatic activity of aconitase and FeS cluster biogenesis enzymes, as well as lower levels of reduced glutathione, implying reduced FeS clusters synthesis/utilization in TICs. Importantly, we have identified specific gene signature related to iron metabolism consisting of genes regulating iron uptake, mitochondrial FeS cluster biogenesis and hypoxic response (ABCB10, ACO1, CYBRD1, EPAS1, GLRX5, HEPH, HFE, IREB2, QSOX1 and TFRC). Principal component analysis based on this signature is able to distinguish TICs from cancer cells in vitro and also Leukemia-initiating cells (LICs) from non-LICs in the mouse model of acute promyelocytic leukemia (APL). Majority of the described changes were also recapitulated in an alternative model represented by MCF7 cells resistant to tamoxifen (TAMR) that exhibit features of TICs. Our findings point to the critical importance of redox balance and iron metabolism-related genes and proteins in the context of cancer and TICs that could be potentially used for cancer diagnostics or therapy.
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.|Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Rychtarcikova
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.|Charles University in Prague, Faculty of Sciences, Prague, Czech Republic.
authors.forename: Sandra
authors.initials: S
authors.lastname: Lettlova
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.|Charles University in Prague, Faculty of Sciences, Prague, Czech Republic.
authors.forename: Veronika
authors.initials: V
authors.lastname: Tomkova
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Vlasta
authors.initials: V
authors.lastname: Korenkova
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Lucie
authors.initials: L
authors.lastname: Langerova
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Simonova
authors.affiliation: Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Polina
authors.initials: P
authors.lastname: Zjablovskaja
authors.affiliation: Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Meritxell
authors.initials: M
authors.lastname: Alberich-Jorda
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.|School of Medical Science, Menzies Health Institute Queensland, Southport, Queensland, Australia.
authors.forename: Jiri
authors.initials: J
authors.lastname: Neuzil
authors.affiliation: Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Truksa
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001692:Biological Transport; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D020869:Gene Expression Profiling; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology; D015473:Leukemia, Promyelocytic, Acute / Q000201:enzymology / Q000235:genetics; D061986:MCF-7 Cells; D008297:Male; D008822:Mice, Transgenic; D008928:Mitochondria / Q000201:enzymology; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D010641:Phenotype; D025341:Principal Component Analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D018874:Spheroids, Cellular; D013629:Tamoxifen / Q000494:pharmacology; D059467:Transcriptome
chemical_list: D000970:Antineoplastic Agents; D007502:Iron Chelating Agents; D013629:Tamoxifen; D007501:Iron
keywords: FeS cluster; breast cancer; iron metabolism; stem cells; tumor-initiating cells